Woodard & Co. Asset Management Group Inc. ADV Has $2.21 Million Stake in Johnson & Johnson (NYSE:JNJ)

Woodard & Co. Asset Management Group Inc. ADV decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 28.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,265 shares of the company's stock after selling 6,065 shares during the quarter. Woodard & Co. Asset Management Group Inc. ADV's holdings in Johnson & Johnson were worth $2,208,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the business. IFS Advisors LLC boosted its position in shares of Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company's stock valued at $25,000 after acquiring an additional 100 shares during the last quarter. Highline Wealth Partners LLC acquired a new position in shares of Johnson & Johnson during the 3rd quarter valued at about $31,000. RPg Family Wealth Advisory LLC acquired a new position in shares of Johnson & Johnson during the 3rd quarter valued at about $35,000. Bay Harbor Wealth Management LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter valued at about $32,000. Finally, Mowery & Schoenfeld Wealth Management LLC boosted its position in shares of Johnson & Johnson by 58.7% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock valued at $40,000 after acquiring an additional 91 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Insider Buying and Selling

In related news, Director Mark A. Weinberger acquired 1,000 shares of the stock in a transaction dated Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Timothy Schmid sold 403 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.16% of the company's stock.

Analyst Ratings Changes

JNJ has been the topic of a number of recent research reports. Wolfe Research initiated coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They set an "outperform" rating and a $190.00 price target on the stock. Citigroup cut their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a research note on Wednesday, December 11th. Royal Bank of Canada reiterated an "outperform" rating and set a $181.00 price target on shares of Johnson & Johnson in a research note on Wednesday. Wells Fargo & Company cut their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating on the stock in a research note on Thursday, January 23rd. Finally, Argus upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research note on Friday, January 24th. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $170.67.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ traded up $2.67 on Friday, hitting $162.35. The company's stock had a trading volume of 12,540,171 shares, compared to its average volume of 9,073,381. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The company has a market capitalization of $390.87 billion, a price-to-earnings ratio of 24.41, a price-to-earnings-growth ratio of 2.53 and a beta of 0.52. The stock's 50-day moving average is $148.61 and its two-hundred day moving average is $155.89. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $22.52 billion during the quarter, compared to analysts' expectations of $22.44 billion. During the same quarter last year, the business posted $2.29 earnings per share. The company's quarterly revenue was up 5.3% on a year-over-year basis. On average, equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.06%. Johnson & Johnson's dividend payout ratio (DPR) is 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.